



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Vorsetuzumab

Cat. No.:	HY-P99273
CAS No.:	1165740-62-4
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Vorsetuzumab (Anti-Human CD70 Recombinant Antibody) is a human anti-CD70 antibody. Vorsetuzumab enhances macrophage-related phagocytosis of renal carcinoma cells, shows inhibitory efficacy against Burkitt's lymphoma ^[1] .	
IC₅₀ & Target	CD70 ^[1]	
In Vitro	Vorsetuzumab (10 µg/mL; 2 h) augments macrophage-dependent phagocytosis of renal carcinoma cells in vitro ^[1] . Vorsetuzumab (10 µg/mL; 2 h) can be developed into bispecific anti-human CD70/KWAR23 antibody, results KWAR23 moderately induced macrophage phagocytosis of four renal carcinoma cell lines (RCC4, RCC10, TK10, and Caki-1) ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
In Vivo	Vorsetuzumab (10 mg/kg; i.p.; every other day; for 12 d) inhibits Burkitt's lymphoma cell growth in SRG mice ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Burkitt's lymphoma xenograft model in SRG mice ^[1]
	Dosage:	10 mg/kg
	Administration:	Intraperitoneal injection; every other day; for 12 d
	Result:	Effectively inhibited Burkitt's lymphoma cell growth but was not outperform the combination of the KWAR23 antibody (10 mg/kg).

REFERENCES

[1]. Ring NG, et al. Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity. Proc Natl Acad Sci U S A. 2017 Dec 5;114(49):E10578-E10585.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA